Widgets for Webmasters
Dendreon Expects Interim Data Analysis For Phase 3 PROVENGE IMPACT Trial In October
medicalnewstoday.com 3 hrs ago 3 relatedDendreon Corporation (Nasdaq: DNDN) announced that it expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT...

